certain early clinical development plans,
87
Table of Content
s
including evaluating the potential of sacituzumab tirumotecan as a monotherapy and in combination with
Keytruda
for advanced solid tumors. Upon option exercise, Merck made a payment of $
30
million, which was recorded as a charge to
Research and development
expenses in 2022. Additionally, Merck made an additional payment of $
25
million upon technology transfer in 2023. Merck has also made all contingent developmental milestone payments under the agreement, which aggregated $
90
million, nearly all of which were paid in 2024 and were recorded to
Research and development
expenses. In addition, Kelun-Biotech is eligible to receive future contingent milestone payments (which include all program compounds) aggregating up to $
290
million in first commercial sale milestones, and $
780
million in sales-based milestones. The agreement also provides for Merck to pay tiered royalties ranging from a mid-single-digit rate to a low-double-digit rate on future net sales.
Spin-Off of Organon & Co.
In connection with the 2021 spin-off of Organon & Co. (Organon), Merck and Organon entered into a series of interim operating agreements pursuant to which in various jurisdictions where Merck held licenses, permits and other rights in connection with marketing, import and/or distribution of Organon products prior to the separation, Merck continued to market, import and distribute such products on behalf of Organon until such time as the relevant licenses and permits transferred to Organon, with Organon receiving all of the economic benefits and burdens of such activities. As of December 31, 2024, only
one
jurisdiction remains under an interim operating agreement. Additionally, Merck and Organon entered into a number of manufacturing and supply agreements (MSAs) with terms ranging from
four years
to
ten years
. The amounts included in the consolidated statement of income for the above MSAs include sales of $
392
million, $
394
million and $
383
million in 2024, 2023 and 2022, respectively, and related cost of sales of $
390
million, $
422
million and $
404
million in 2024, 2023 and 2022, respectively. The amounts due from Organon under all spin-off related agreements were $
330
million and $
632
million at December 31, 2024 and 2023, respectively, and are reflected in
Other current assets
. The amounts due to Organon under these agreements were $
113
million and $
598
million at December 31, 2024 and 2023, respectively, and are included in
Accrued and other current liabilities
.
4.
Collaborative Arrangements
Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. Both parties in these arrangements are active participants and exposed to significant risks and rewards dependent on the commercial success of the activities of the collaboration. Merckâ€™s more significant collaborative